题目：DiscoveryofASTX727(INQOVI)，an oral combination of decitabine and cedazuridine for the treatment of myelodysplastic syndromes(MDS)
报告人：Takashi Tsukamoto,Ph.D. is Associate Professor of Neurology at Johns Hopkins University and the Director of Medicinal Chemistry atJohns Hopkins Drug Discovery Program. Dr. Tsukamoto received his Ph.D. degree in Chemistry from Tokyo Institute of Technology and pursued postdoctoral studies in the Department of Medicinal Chemistry at the University of Michigan. Prior to joining Johns Hopkins in 2009, Dr. Tsukamoto has held a variety of research positions in the pharmaceutical industry including Guilford Pharmaceuticals, MGI Pharma, and the Eisai Research Institute. During the course of his career, he has served as a lead medicinal chemist in a number of drug discovery projects exploring new therapeutics for neurological disorders and cancer. At the Johns Hopkins Drug Discovery Program, Dr. Tsukamoto leads a team of medicinal chemists involved in the design and synthesis of small molecules of therapeutic significance in various projects.
参会方式：腾讯会议会议ID：692 394 060 会议密码：4321